Embecta (NASDAQ:EMBC – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.700-2.900 for the period, compared to the consensus EPS estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Embecta Stock Performance
Shares of NASDAQ:EMBC opened at $14.41 on Tuesday. Embecta has a 52-week low of $9.93 and a 52-week high of $19.79. The stock has a market capitalization of $831.46 million, a price-to-earnings ratio of 12.01 and a beta of 0.97. The stock’s 50-day simple moving average is $14.33 and its two-hundred day simple moving average is $14.04.
Embecta Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 4.16%. Embecta’s dividend payout ratio (DPR) is 50.00%.
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
See Also
- Five stocks we like better than Embecta
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- Are Penny Stocks a Good Fit for Your Portfolio?
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- What is MarketRank™? How to Use it
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
